Biomarker Testing In Non–Small Cell Lung Cancer - Episode 5

Treatment Planning After Biomarker Testing in NSCLC

, ,

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.

EP. 1: The Role of Biomarker Testing in Metastatic and Resectable NSCLC
EP. 2: When to Conduct Molecular Testing in NSCLC
EP. 3: The Utility of Rapid Lung NGS for Biomarker Testing in NSCLC
EP. 4: The Specificity/Sensitivity of Rapid Lung NGS for Biomarker Testing in NSCLC
Now Viewing
EP. 5: Treatment Planning After Biomarker Testing in NSCLC
EP. 6: Benefits of In-House Biomarker Testing in NSCLC
EP. 7: Tissue vs Liquid Biopsies for Biomarker Testing in NSCLC
EP. 8: How Biomarker Testing Could Continue to Evolve in NSCLC

Related Content:

Biomarker Testing In Non–Small Cell Lung CancerLung CancerPrecision Medicine in Oncology®
Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation
Dr Pobel on the Prognostic Value of Phenotypic and Genomic Characterization in De Novo mCSPC
Zorifertinib Receives NMPA Approval for EGFR+ NSCLC With CNS Metastases